The Filing Desk

Exelixis vs Moderna

Exelixis EXEL · Moderna MRNA · Biotechnology

Exelixis reported revenue of $2.3 billion in fiscal 2025, 1.2 times Moderna's $1.9 billion in fiscal 2025. Exelixis' revenue grew 7.0% in its latest year, and Moderna's fell 39.9%. Exelixis had an operating margin of 37.6%, against -158.1% at Moderna. Free cash flow was $876 million at Exelixis and −$2.1 billion at Moderna. Their fiscal years end in different months (January 2 and December 31), so the periods don't line up exactly.

Side by side

ExelixisModerna
Latest fiscal yearFY2025, Jan 2, 2026FY2025, Dec 31, 2025
Revenue$2.3B$1.9B
Revenue growth7.0%−39.9%
Revenue growth a year, last 5 years18.6%19.3%
Gross margin96.4%55.4%
Operating margin37.6%−158.1%
Net margin33.7%−145.2%
Free cash flow$876M−$2.1B
Free cash flow margin37.8%−106.2%
Return on capital64.9%−65.4%
Net debt to EBITDA−1.2x—
Dividends and buybacks$948M$2M
Change in diluted share count−4.8%1.3%
Last close$65.11$198.85
P/E at the last close20.5×—
Insider trades, last 12 monthsbought $1.2 million, sold $42.2 millionsold $81.6 million
Piotroski F-score6 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ExelixisModerna
Operating margin
Percent of revenue
ExelixisModerna
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ExelixisModerna

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Exelixis and Moderna pages.